Compare CXAI & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXAI | PLUR |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 34.9M |
| IPO Year | N/A | N/A |
| Metric | CXAI | PLUR |
|---|---|---|
| Price | $0.39 | $3.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.8M | 44.2K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,222,000.00 | $1,326,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | $70.21 | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 121.74 |
| 52 Week Low | $0.36 | $2.82 |
| 52 Week High | $2.54 | $7.13 |
| Indicator | CXAI | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 48.89 |
| Support Level | $0.37 | $2.82 |
| Resistance Level | $0.42 | $3.72 |
| Average True Range (ATR) | 0.06 | 0.33 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 11.50 | 52.73 |
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.